Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CS 101

Next Previous
X
Search
Drug Profile

CS 101

Alternative Names: CS-101

Latest Information Update: 05 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CorrectSequence Therapeutics
  • Developer CorrectSequence Therapeutics; The First Affiliated Hospital Of Guangxi Medical University
  • Class Gene therapies; Haematopoietic stem cells therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Beta-thalassaemia
  • Preclinical Sickle cell anaemia

Most Recent Events

  • 18 Jun 2024 Children's Hospital of Fudan University initiates a clinical trial for Beta-thalassemia (In Children, In adolescents) in China (Parenteral) (NCT06479616)
  • 18 Apr 2024 Phase-I clinical trials in Beta-thalassaemia (In children, In adolescents, In adults) in China (Parenteral) (NCT06291961)
  • 20 Mar 2024 CorrectSequence Therapeutics plans an early phase I trial for Beta-thallassemia in China (NCT06328764)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top